Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Bestgen

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cold Spring Harbor Perspectives in Medicine|June 29, 2026
New Malaria Prevention Modalities: Long-Acting Interventions Beyond VaccinesCristina Donini, Richard K Amewu, Benoit Bestgen, et al.
Journal of Medicinal Chemistry|March 25, 2016
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase InhibitorsBénédicte Daydé-Cazals, Bénédicte Fauvel, Mathilde Singer, et al.
British Journal of Clinical Pharmacology|February 17, 2025
First-in-human safety, tolerability, pharmacokinetics and pilot food-effect study of the candidate antimalarial compound MMV367Andrea Kuemmerle, Nand Singh, Denis Gossen, et al.
British Journal of Clinical Pharmacology|May 29, 2025
First-in-human safety, tolerability, pharmacokinetics and pilot food-effect study of the candidate antimalarial compound MMV367Andrea Kuemmerle, Nand Singh, Denis Gossen, et al.
Scientific Reports|November 6, 2019
Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitorsIrina Kufareva, Benoit Bestgen, Paul Brear, et al.
The Lancet. Infectious Diseases|December 21, 2024
Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection studyBenoit Bestgen, Sam Jones, Vandana Thathy, et al.
Science Translational Medicine|June 10, 2026
The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage <i>Plasmodium falciparum</i> in healthy adults with experimental malariaBridget E Barber, Robin Denhardt-Eriksson, Etienne A Guirou, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cold Spring Harbor Perspectives in Medicine|June 29, 2026
New Malaria Prevention Modalities: Long-Acting Interventions Beyond VaccinesCristina Donini, Richard K Amewu, Benoit Bestgen, et al.
Journal of Medicinal Chemistry|March 25, 2016
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase InhibitorsBénédicte Daydé-Cazals, Bénédicte Fauvel, Mathilde Singer, et al.
British Journal of Clinical Pharmacology|February 17, 2025
First-in-human safety, tolerability, pharmacokinetics and pilot food-effect study of the candidate antimalarial compound MMV367Andrea Kuemmerle, Nand Singh, Denis Gossen, et al.
British Journal of Clinical Pharmacology|May 29, 2025
First-in-human safety, tolerability, pharmacokinetics and pilot food-effect study of the candidate antimalarial compound MMV367Andrea Kuemmerle, Nand Singh, Denis Gossen, et al.
Scientific Reports|November 6, 2019
Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitorsIrina Kufareva, Benoit Bestgen, Paul Brear, et al.
The Lancet. Infectious Diseases|December 21, 2024
Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection studyBenoit Bestgen, Sam Jones, Vandana Thathy, et al.
Science Translational Medicine|June 10, 2026
The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage <i>Plasmodium falciparum</i> in healthy adults with experimental malariaBridget E Barber, Robin Denhardt-Eriksson, Etienne A Guirou, et al.
Pageof 1